{"title":"Chinese herbal medicines and its active ingredient wogonin can improve immune inflammation in psoriatic arthritis","authors":"Xian-Heng Zhang , Jian Liu , Xiang Ding , Xiao-Lu Chen","doi":"10.1016/j.intimp.2024.113984","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>In China, Chinese herbal medicines (CHMs) have been widely used in the treatment of psoriatic arthritis (PsA), showing great therapeutic effects in clinical practice. However, due to the great heterogeneity of PsA and the diversity of CHM combination patterns, there is little high-level evidence-based medical research on the treatment of PsA with CHMs. This study aims to explore the beneficial effects of CHMs on the immune inflammation in PsA and its specific mechanism.</div></div><div><h3>Methods</h3><div>The data mining method was performed to analyze the real-world data of 91 PsA clinical cases. Network pharmacology, molecular docking, and cellular experiments were used to explore the mechanism of CHMs and its active ingredient wogonin in improving PsA immune inflammation.</div></div><div><h3>Results</h3><div>Data mining results showed that in PsA, immune inflammation was disturbed and relevant indexes were significantly correlated. After CHM treatment, the level of HCRP, C4, IL-12, IL-17, IL-23, TNF-α, TGF-β1, P65, P50, and IKBα was markedly improved, which was highly correlated with the application of CHMs. In addition, the core prescription containing 10 CHMs was screened, and the action mechanisms of the active ingredient wogonin on the immune inflammation in PsA were identified with network pharmacology and molecular docking. Cell experiments revealed that wogonin reduced M5-induced HaCaT cell viability and TNF-α and IL-1β expressions by blocking the PI3K/AKT pathway in a dose-dependent manner.</div></div><div><h3>Conclusion</h3><div>Our findings strongly confirmed the enormous promise of CHMs as a therapy for PsA and may provide support for developing drugs and targets for PsA treatment.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"147 ","pages":"Article 113984"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576924025062","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
In China, Chinese herbal medicines (CHMs) have been widely used in the treatment of psoriatic arthritis (PsA), showing great therapeutic effects in clinical practice. However, due to the great heterogeneity of PsA and the diversity of CHM combination patterns, there is little high-level evidence-based medical research on the treatment of PsA with CHMs. This study aims to explore the beneficial effects of CHMs on the immune inflammation in PsA and its specific mechanism.
Methods
The data mining method was performed to analyze the real-world data of 91 PsA clinical cases. Network pharmacology, molecular docking, and cellular experiments were used to explore the mechanism of CHMs and its active ingredient wogonin in improving PsA immune inflammation.
Results
Data mining results showed that in PsA, immune inflammation was disturbed and relevant indexes were significantly correlated. After CHM treatment, the level of HCRP, C4, IL-12, IL-17, IL-23, TNF-α, TGF-β1, P65, P50, and IKBα was markedly improved, which was highly correlated with the application of CHMs. In addition, the core prescription containing 10 CHMs was screened, and the action mechanisms of the active ingredient wogonin on the immune inflammation in PsA were identified with network pharmacology and molecular docking. Cell experiments revealed that wogonin reduced M5-induced HaCaT cell viability and TNF-α and IL-1β expressions by blocking the PI3K/AKT pathway in a dose-dependent manner.
Conclusion
Our findings strongly confirmed the enormous promise of CHMs as a therapy for PsA and may provide support for developing drugs and targets for PsA treatment.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.